.Pharmacolibrary.Drugs.N_NervousSystem.N02C_AntimigrainePreparations.N02CC01_Sumatriptan.Sumatriptan

Information

Sumatriptan is a selective serotonin (5-HT1B/1D) receptor agonist used primarily for the acute treatment of migraine attacks with or without aura. It is approved for use and is considered effective in aborting migraine headaches.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult subjects following a single oral dose administration.

References

1. Ohk, B, et al., & Yoo, H (2022). Evaluation of sex differences in the pharmacokinetics of oral sumatriptan in healthy Korean subjects using population pharmacokinetic modeling. Biopharmaceutics & drug disposition 43(1) 23–32. DOI:10.1002/bdd.2307 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34923646

2. Fuseau, E, et al., & Ibbotson, T (2002). Clinical pharmacokinetics of intranasal sumatriptan. Clinical pharmacokinetics 41(11) 801–811. DOI:10.2165/00003088-200241110-00002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12190330

3. Dilone, E, et al., & Fox, AW (2009). Rapid oral transmucosal absorption of sumatriptan, and pharmacodynamics in acute migraine. Headache 49(10) 1445–1453. DOI:10.1111/j.1526-4610.2009.01475.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/19549162

Revisions

• 06/2025 initial generated model